4+ day, 19+ hour ago   (159+ words) PharmaDispatch Australia secures sovereign viral vector manufacturing as VVMF wins TGA licence A Sydney company has become the first in Australia to earn a manufacturing licence for viral vectors, a milestone it says strengthens the nation's capacity to make advanced…...

2+ week, 14+ hour ago   (140+ words) PharmaDispatch Alterity secures option underwriting as it prepares for pivotal MSA trial Alterity Therapeutics has secured an underwriting agreement that could provide at least $4.2 million in additional funding as the company prepares to begin its planned Phase 3 clinical trial of…...

2+ week, 19+ hour ago   (131+ words) PharmaDispatch Astellas Australia turns to rare disease leader Guillaume Pfeiffer for next chapter Astellas Australia has appointed Guillaume Pfeiffer as its new general manager, bringing more than two decades of experience across specialty medicines, rare diseases, oncology and advanced therapies…...

2+ week, 5+ day ago   (142+ words) PharmaDispatch Genetic Signatures and Microba explore merger to build infectious disease diagnostics group Genetic Signatures and Microba Life Sciences have announced they are in preliminary discussions about a potential merger that would combine rapid infectious disease testing with gut microbiome…...

3+ week, 6+ day ago   (136+ words) PharmaDispatch Opportunity #1 - biosimilar policy failure has become impossible to ignore If the promise of biosimilars is only savings for the government, rather than savings and wider access, what is the point from a patient perspective? The one-dimensional focus on savings…...